Myasthenia Gravis: a Review

• Matsumoto Hideyuki

  Department of Neurology, Japanese Red Cross Medical Center

• Ugawa Yoshikazu

  Department of Neurology, School of Medicine, Fukushima Medical University

抄録

Myasthenia gravis (MG) is an auto-immune disorder caused by neuromuscular transmission failure, and is a representative post-neuromuscular junctional disorder. The most common auto-immune antibody is the anti-acetylcholine receptor (AChR) antibody, which is detected in approximately 80 to 85% of MG patients. Recently, auto-immune antibodies against the muscle-specific receptor tyrosine kinase (MuSK) and the LDL-receptor related protein 4 (Lrp4) have also been found. The clinical symptoms and therapeutic responses are highly dependent on the types of auto-immune antibodies. Thymectomy is a common treatment for MG, although a recent meta-analysis on thymectomy did not show any clinical benefit. Several new immune-mediated therapies have become available and the therapeutic strategy is currently changing drastically. In the future, the establishment of a novel therapeutic strategy is expected for this disorder.

収録刊行物

• Journal of General and Family Medicine

  Journal of General and Family Medicine 17 (3), 211-217, 2016

  一般社団法人 日本プライマリ・ケア連合学会

キーワード

• myasthenia gravis (MG)
• anti-acetylcholine receptor (AChR) antibody
• anti-muscle-specific receptor tyrosine kinase (MuSK) antibody
• anti-LDL-receptor related protein 4 receptor (Lrp4) antibody
• repetitive nerve stimulation test

詳細情報

• CRID: 1390001205763436544
• NII論文ID: 130005267181
• DOI: 10.14442/jgfm.17.3_211
• ISSN: 21897948
• ISSN: 21896577
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.14442%2Fjgfm.17.3_211
• Web Site: https://onlinelibrary.wiley.com/doi/pdf/10.14442/jgfm.17.3_211
• Web Site: https://search.jamas.or.jp/link/ui/2017210120
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可